Form 4: Kathleen Laporte Acquires 22,000 Stock Options in Bolt Biotherapeutics

Director Kathleen Laporte acquired 22,000 stock options in Bolt Biotherapeutics on June 12, 2024, at an exercise price of $0.7682.

Summary

• Kathleen Laporte, a director of Bolt Biotherapeutics, Inc. [BOLT], acquired 22,000 stock options on June 12, 2024.
• The exercise price of these options is $0.7682.
• The options vest on the earlier of June 12, 2025, or the day before the next annual meeting of stockholders, contingent upon continuous service.
• Full vesting occurs upon a change in control of the Issuer.
• The options expire on June 11, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of stock options by a director could be interpreted as a mildly positive signal, suggesting confidence in the company's prospects.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates